Oral delivery of oligonucleotides

NZ835116APending Publication Date: 2026-07-31CIVI BIOPHARMA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
NZ835116
Authority / Receiving Office
NZ · NZ
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-10
Filing Date
2022-04-21
Publication Date
2026-07-31

Smart Images

  • Figure 00000215_0000
    Figure 00000215_0000
  • Figure 00000215_0001
    Figure 00000215_0001
  • Figure 00000216_0000
    Figure 00000216_0000
Patent Text Reader

Abstract

The present disclosure provides oligonucleotide compositions comprising (1) an oligonucleotide of the present disclosure, e.g., an ASO, siRNA, shRNA, DNA or RNA aptamer, gene therapy vector, miRNA, miRNA mimic, antimiR, DNA or RNA decoy, CpG oligonucleotide, or any therapeutic or diagnostic oligonucleotide known in the art, and (ii) a caprylic acid derivative, e.g., 5-CNAC. In some aspects, the oligonucleotide composition is formulated for delivery to the gastrointestinal tract. Thus, some aspects, the present disclosure provides oligonucleotide compositions for oral delivery comprising a therapeutic or diagnostic oligonucleotide (e.g., an ASO) and a caprylic acid derivative (e.g., 5-CNAC or de derivative thereof).
Need to check novelty before this filing date? Find Prior Art